End-of-day quote
Philippines S.E.
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
0.73
PHP
|
-6.41%
|
|
0.00%
|
-2.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,991
|
6,579
|
9,622
|
5,757
|
3,578
|
3,084
|
Enterprise Value (EV)
1 |
9,194
|
9,156
|
12,481
|
8,450
|
6,452
|
6,040
|
P/E ratio
|
18.9
x
|
17.8
x
|
46.8
x
|
34.1
x
|
17.9
x
|
10.7
x
|
Yield
|
4.12%
|
3.13%
|
0.64%
|
1.43%
|
4.02%
|
-
|
Capitalization / Revenue
|
1.34
x
|
1.16
x
|
2.51
x
|
1.6
x
|
0.85
x
|
0.59
x
|
EV / Revenue
|
1.77
x
|
1.61
x
|
3.26
x
|
2.36
x
|
1.53
x
|
1.15
x
|
EV / EBITDA
|
10.4
x
|
9.14
x
|
16.4
x
|
13.2
x
|
9.72
x
|
6.78
x
|
EV / FCF
|
84.2
x
|
536
x
|
-155
x
|
68.4
x
|
-113
x
|
2,447
x
|
FCF Yield
|
1.19%
|
0.19%
|
-0.65%
|
1.46%
|
-0.89%
|
0.04%
|
Price to Book
|
1.31
x
|
1.21
x
|
1.77
x
|
1.02
x
|
0.63
x
|
0.53
x
|
Nbr of stocks (in thousands)
|
4,112,141
|
4,112,141
|
4,112,141
|
4,112,141
|
4,112,141
|
4,112,141
|
Reference price
2 |
1.700
|
1.600
|
2.340
|
1.400
|
0.8700
|
0.7500
|
Announcement Date
|
4/15/19
|
6/29/20
|
4/30/21
|
5/10/22
|
4/18/23
|
4/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,208
|
5,688
|
3,829
|
3,587
|
4,224
|
5,264
|
EBITDA
1 |
885.5
|
1,002
|
763
|
639
|
664.1
|
890.7
|
EBIT
1 |
661.6
|
760.9
|
540.7
|
411.1
|
440.4
|
652.6
|
Operating Margin
|
12.7%
|
13.38%
|
14.12%
|
11.46%
|
10.43%
|
12.4%
|
Earnings before Tax (EBT)
1 |
536.9
|
557.1
|
305
|
231.4
|
280.3
|
398.4
|
Net income
1 |
373.9
|
388.9
|
210.1
|
169
|
199.9
|
289.9
|
Net margin
|
7.18%
|
6.84%
|
5.49%
|
4.71%
|
4.73%
|
5.51%
|
EPS
2 |
0.0900
|
0.0900
|
0.0500
|
0.0411
|
0.0486
|
0.0700
|
Free Cash Flow
1 |
109.2
|
17.09
|
-80.75
|
123.6
|
-57.12
|
2.469
|
FCF margin
|
2.1%
|
0.3%
|
-2.11%
|
3.45%
|
-1.35%
|
0.05%
|
FCF Conversion (EBITDA)
|
12.33%
|
1.71%
|
-
|
19.34%
|
-
|
0.28%
|
FCF Conversion (Net income)
|
29.19%
|
4.39%
|
-
|
73.12%
|
-
|
0.85%
|
Dividend per Share
2 |
0.0700
|
0.0500
|
0.0150
|
0.0200
|
0.0350
|
-
|
Announcement Date
|
4/15/19
|
6/29/20
|
4/30/21
|
5/10/22
|
4/18/23
|
4/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2,203
|
2,577
|
2,859
|
2,693
|
2,874
|
2,956
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.488
x
|
2.572
x
|
3.747
x
|
4.215
x
|
4.328
x
|
3.318
x
|
Free Cash Flow
1 |
109
|
17.1
|
-80.7
|
124
|
-57.1
|
2.47
|
ROE (net income / shareholders' equity)
|
7.1%
|
7.2%
|
3.85%
|
3.05%
|
3.52%
|
5.02%
|
ROA (Net income/ Total Assets)
|
4.43%
|
4.75%
|
3.31%
|
2.6%
|
2.79%
|
3.92%
|
Assets
1 |
8,446
|
8,181
|
6,343
|
6,501
|
7,171
|
7,402
|
Book Value Per Share
2 |
1.300
|
1.330
|
1.320
|
1.370
|
1.390
|
1.420
|
Cash Flow per Share
2 |
0.2500
|
0.2700
|
0.1200
|
0.1300
|
0.1500
|
0.2100
|
Capex
1 |
682
|
582
|
451
|
286
|
88.9
|
292
|
Capex / Sales
|
13.1%
|
10.24%
|
11.77%
|
7.96%
|
2.1%
|
5.54%
|
Announcement Date
|
4/15/19
|
6/29/20
|
4/30/21
|
5/10/22
|
4/18/23
|
4/15/24
|
|
1st Jan change
|
Capi.
|
---|
| -2.67% | 51.1M | | +20.14% | 43.3B | | +23.67% | 22.22B | | +15.93% | 15.43B | | +23.10% | 14.48B | | +57.58% | 12.72B | | -0.05% | 6.79B | | -10.69% | 6.71B | | -8.87% | 5.73B | | +14.68% | 5.5B |
Generic Pharmaceuticals
|